Patents by Inventor Manolis PASPARAKIS

Manolis PASPARAKIS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combinations of RIPK- and IKK-inhibitors for the prevention or treatment of immune diseases
    Patent number: 12678447
    Abstract: The present invention pertains to the treatment of diseases associated with a dysregulated immune response such as auto immune disorders, inflammatory diseases or pathological immune responses as adverse effects of medical treatments. In particular the invention provides a combined use of inhibitors of Receptor-interacting serine/threonine-protein kinase (RIPK1) and inhibitors of Inhibitor of ?B (I?B) Kinase (IKK) in subjects suffering from such disorders. The invention provides such inhibitory compounds and their combinations for use in medical applications, as well as pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: July 14, 2026
    Assignee: Universität zu Köln
    Inventors: Manolis Pasparakis, Nikos Oikonomou, Apostolos Polykratis
  • SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES
    Publication number: 20250082652
    Abstract: The present invention pertains to the treatment of proliferative diseases, such as cancer. In particular, the invention describes a novel combination therapy strategy, comprising a Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, an Inhibitor of ?B (I?B) Kinase (IKK)/Nuclear Factor ?B (NF?B)-signaling inhibitor, and a B-cell lymphoma 2 (BCL-2) inhibitor for the treatment and/or prevention of proliferative diseases, such as cancer. The invention provides such inhibitory compounds and their combinations for use in medical applications, as well as pharmaceutical compositions comprising the compounds of the invention.
    Type: Application
    Filed: December 30, 2022
    Publication date: March 13, 2025
    Applicant: UNIVERSITÄT ZU KÖLN
    Inventors: Manolis PASPARAKIS, Simon FALLAIS, Gero KNITTEL, Christian REINHARDT
  • COMBINATIONS OF RIPK1- AND IKK-INHIBITORS FOR THE PREVENTION OR TREATMENT OF IMMUNE DISEASES
    Publication number: 20200383995
    Abstract: The present invention pertains to the treatment of diseases associated with a dysregulated immune response such as auto immune disorders, inflammatory diseases or pathological immune responses as adverse effects of medical treatments. In particular the invention provides a combined use of inhibitors of Receptor-interacting serine/threonine-protein kinase (RIPK1) and inhibitors of Inhibitor of ?B (I?B) Kinase (IKK) in subjects suffering from such disorders. The invention provides such inhibitory compounds and their combinations for use in medical applications, as well as pharmaceutical compositions comprising the compounds of the invention.
    Type: Application
    Filed: December 7, 2018
    Publication date: December 10, 2020
    Applicant: Universität zu Köln
    Inventors: Manolis PASPARAKIS, Nikos OIKONOMOU, Apostolos POLYKRATIS